Global Biosimilar Testing and Development Services Market Size By Type (Effector Binding, ELISA), By Application (PK assay, Tiered Immunogenicity testing), By Region, And Segment Forecasts, 2023 to 20...

lobal Biosimilar Testing and Development Services Market Report Description

The Global Biosimilar Testing and Development Services Market was valued at USD 2.9 billion in 2023 and is projected to reach USD 6.8 billion by 2031, growing at a CAGR of 11.3% during the forecast period (2023–2031).

The market growth is primarily driven by the expiring patents of blockbuster biologics, increasing demand for affordable biologics, and rising investment in biosimilar R&D. Biosimilar testing and development services play a crucial role in ensuring regulatory compliance, analytical comparability, and clinical safety, supporting the successful commercialization of biosimilars worldwide.

Additionally, the increasing adoption of advanced analytical techniques, regulatory harmonization, and outsourcing of testing services to specialized CROs (Contract Research Organizations) are accelerating market expansion.

Drivers

Patent Expiry of Key Biologics

The growing wave of biologic patent expirations opens the door for biosimilar development, creating a significant demand for testing and development services.

Cost-Effective Alternatives for Biologics

Rising healthcare costs and the need for affordable biologic therapies are propelling biosimilar adoption, directly driving demand for testing and regulatory services.

Advancements in Analytical & Bioassay Technologies

Rapid innovation in analytical characterization, bioassays, and immunogenicity testing enhances the accuracy and efficiency of biosimilar testing, fostering market growth.

Increasing Outsourcing Trends

Biopharma companies are increasingly outsourcing biosimilar testing to specialized CROs to reduce cost and improve turnaround times.

Restraints

Stringent Regulatory Requirements

Complex and evolving regulatory frameworks across regions can increase time and cost burdens for biosimilar developers.

High Development and Testing Costs

Despite being cheaper than innovator biologics, biosimilar development still demands substantial investments in analytical testing, clinical trials, and manufacturing.

Limited Biosimilar Awareness in Emerging Markets

Low physician and patient awareness in certain developing regions can hinder biosimilar penetration and indirectly affect the demand for testing services.

Opportunities

Rising Demand in Emerging Markets

Increasing healthcare access and growing biologics demand in Asia-Pacific and Latin America create lucrative opportunities for biosimilar development.

Integration of AI & Automation in Biosimilar Testing

The use of AI-driven analytics and automated bioassays is improving biosimilar comparability testing and reducing timelines.

Collaborations with CROs & CDMOs

Strategic partnerships between biosimilar developers and contract organizations are expected to accelerate testing and development pipelines.

Market by Service Type Insights

Analytical Testing Services accounted for the largest market share in 2023, driven by the increasing need for comparability studies and structural characterization.

Bioassay & Immunogenicity Testing Services are expected to witness the fastest growth, supported by stringent regulatory requirements for safety and efficacy validation.

Market by End-Use Insights

Biopharmaceutical Companies dominate the market, accounting for more than 60% share in 2023, as they are the primary users of biosimilar testing services.

Contract Research Organizations (CROs) are expected to grow at the highest CAGR due to the increasing trend of outsourcing biosimilar testing and development.

Market by Regional Insights

North America led the market in 2023, driven by a strong regulatory framework (FDA), well-established biopharma industry, and early adoption of biosimilars.

Europe holds a significant share due to supportive policies from EMA and high biosimilar acceptance rates.

Asia-Pacific is expected to record the fastest growth during 2023–2031, fueled by cost-effective biosimilar development hubs in India, South Korea, and China.

Competitive Scenario

Key players in the Global Biosimilar Testing and Development Services Market include:

Charles River Laboratories

Eurofins Scientific

WuXi AppTec

SGS SA

Labcorp Drug Development

ICON plc

PRA Health Sciences

BioOutsource (Sartorius Stedim BioOutsource)

These companies focus on advanced bioanalytical platforms, regulatory expertise, and strategic acquisitions to expand their service portfolios and strengthen their global presence.

Recent Developments:

In 2024, Eurofins Scientific launched an AI-powered biosimilar comparability testing platform to accelerate analytical assessments.

WuXi AppTec expanded its biologics testing facility in China in 2023 to cater to growing biosimilar demand in the Asia-Pacific region.

Charles River Laboratories partnered with leading biosimilar developers in 2023 to enhance end-to-end biosimilar development services.

Scope of Work – Global Biosimilar Testing and Development Services Market

Key Market Developments

2024: Eurofins Scientific introduced a next-gen analytical platform for biosimilar glycosylation profiling.

2023: Charles River Laboratories partnered with a major biopharma firm for an end-to-end biosimilar development program.

2023: WuXi AppTec expanded its U.S. biosimilar testing capabilities with enhanced bioassay automation.

FAQs

What is the current market size of the Global Biosimilar Testing and Development Services Market?

The market was valued at USD 2.9 billion in 2023.

What is the major growth driver of the Global Biosimilar Testing and Development Services Market?

The key driver is the patent expiry of blockbuster biologics and the increasing demand for affordable biosimilar alternatives.

Which is the largest region during the forecast period in the Global Biosimilar Testing and Development Services Market?

North America remains the leading region, while Asia-Pacific is expected to grow the fastest.

Which segment accounted for the largest market share in Global Biosimilar Testing and Development Services Market?

Analytical Testing Services held the largest share in 2023.

Who are the key market players in the Global Biosimilar Testing and Development Services Market?

Major players include Charles River Laboratories, Eurofins Scientific, WuXi AppTec, SGS SA, and Labcorp Drug Development.

Would you like me to create another similar structured report for a different topic, or should I also generate a brief infographic summary for this market?